Navigation Links
New advances in genetic studies of Fanconi anemia patients
Date:3/2/2011

  • An international consortium of researchers led by Universitat Autnoma de Barcelona (UAB) genetically characterises almost all Spanish patients and studies the clinical impact of the mutations.
  • The study describes over 130 pathogenic mutations and the origins and world distribution of some of the most frequent mutations.
  • The predominant genetic mutation originated in Europe thousands of years ago and later migrated to America. The Canary island of La Palma and Brazil, with a high prevalence of the disease, were two areas in which the mutation spread widely.

A consortium of thirty-two researchers worldwide, led by Dr Jordi Surralls, professor of the Department of Genetics and Microbiology at Universitat Autnoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.

A hundred people in Spain suffer from Fanconi anaemia; 80% of these present mutations in the FANCA gene. In the research, 90% of these patients were studied, as well as patients in Brazil, Mexico, Argentina, Peru, United States, United Kingdom, Portugal, Germany, Pakistan and Nigeria.

The research includes characterisation of over 130 pathogenic mutations in the FANCA gene, present in two of every three cases in almost all of the countries analysed, as well as the study of the origin and world distribution of some of the most frequent mutations. The mutation predominating in Spain and in the rest of countries is an ancestral mutation of Indo-European origin which spread throughout Europe thousands of years ago and which reached America across the Atlantic, producing founder effects in areas such as La Palma, with a high prevalence o
'/>"/>

Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Page: 1 2

Related biology news :

1. Annual Bibliography of Significant Advances in Dietary Supplement Research 2007
2. New book includes advances in the science and practice of transfusion and transplantation
3. State fund advances titanium powder research, 9 other Iowa State projects
4. Evolution and climate change research advances at Rutgers-Camden
5. Iowa Power Fund advances researcher’s long quest for efficient solar power
6. Salient Stills Notches Significant Advances in Profitability, Diversity of Sales and Customers, and Video Forensics Technology in 2008
7. Olympus advances technology for laparo-endoscopic single-site surgery
8. New hope for advances in treating malaria
9. Using combinatorial libraries to engineer genetic circuits advances synthetic biology
10. Advances in lung cancer research announced at conference
11. JDRF-funded research advances potential for regeneration as a possible cure for type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... For coffee lovers, the first cup of the morning is one ... grounds could eliminate one of the worst smells around sewer ... remove toxic gases from the air, scientists at The City College ... coffee grounds can sop up hydrogen sulfide gas, the chemical that ...
... DURHAM, N.H. Americans, knowledge of facts about the ... but this increase in knowledge has not translated into ... research from the Carsey Institute at the University of ... issues improved from 2006 to 2010, consistent with hopes ...
... Second Class? Confronting the Risks to U.S. ... Research Foruma unique interactive gathering of top policy ... agencies for health research, as well as nationally ... Two panels will each be followed by Q&A, ...
Cached Biology News:Carbonized coffee grounds remove foul smells 2Carsey Institute: Americans' knowledge of polar regions up, but not their concern 2World class to second class? Confronting the risks to US science and innovation 2
(Date:5/30/2015)... The Cholangiocarcinoma Foundation (CCF), a ... duct cancer, announced today the first grant recipients ... , The Foundation has awarded 5 grants ... to raise awareness about cholangiocarcinoma and inspire innovative, ... opens new pathways for diagnosis and drug discovery ...
(Date:5/30/2015)... , May 30, 2015 CTI BioPharma ... International,s Bioscience business (NYSE: BAX ) today announced ... trial examining pacritinib for the treatment of myelofibrosis – ... Annual Meeting of the American Society of Clinical Oncology ... Ill. Pacritinib is an investigational oral multikinase ...
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 /PRNewswire/ ... Phase 2 MMY2002 (SIRIUS) trial show treatment with ... antibody – achieved an overall response rate (ORR) ... by an independent review committee, in heavily pre-treated ... among the pre-specified subgroups based on age, prior ...
(Date:5/30/2015)... IRVING, Texas , May 30, 2015 /PRNewswire/ ... data from a study in which researchers identified ... of metachronous paired glioma tumors, indicating changes in ... study observing 19 patients was a subset of ... confirmed molecular heterogeneity of the cancer. These data ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... , CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. ... raise approximately $3.1 million in gross proceeds, before deducting placement agent ... of 9.5 million units, at a price of $0.33 per unit. ... and (ii) a warrant exercisable at any time on or after ...
... , OMAHA, Neb., Aug. 12 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... 2009 @ 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... at the, address above., ...
... , , WALTHAM, Mass., ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... share in second- and third-line therapy since last year,s analysis ... attributed to the publication of the ENHANCE trial which called ...
Cached Biology Technology:Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering 2Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering 3Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3